Carfilzomib
Carfilzomib is a drug used to treat Multiple Myeloma, Recurrent Plasma Cell Myeloma, Lymphoma, and other conditions. Carfilzomib is being actively studied in 83 studies and prior, has been studied in 56.
Top Sponsors | Top Sites | Top Investigators |
---|---|---|
Amgen | Hackensack University Medical Center | Jonathan Kaufman |
M.D. Anderson Cancer Center | Mayo Clinic | Ajai Chari |
National Cancer Institute (NCI) | Washington University School of Medicine | Ajay Nooka |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Completed
- Hematologic Malignancies
- +2 more
- Carfilzomib
- Tacrolimus
- Ann Arbor, MichiganUniversity of Michigan Hospital
2021-12-03
Dec 3, 2021C
Terminated
- Hodgkin Disease
- Lymphoma, Non-hodgkin
- Carfilzomib
- TGR-1202
- New York, New YorkColumbia University Irving Medical Center - Center for Lymphoid
2021-06-28
Jun 28, 2021P
Recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Isatuximab
- +3 more
- Poitiers, FranceCHU Poitiers
2021-11-25
Nov 25, 2021L
Recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
- Maywood, IllinoisLoyola University Medical Center
2021-04-23
Apr 23, 2021i
Recruiting
- Multiple Myeloma in Relapse
- Carfilzomib
- Frankfurt, GermanyCentrum für Hämatologie und Onkologie Bethanien
2021-04-12
Apr 12, 2021T
Recruiting
- Multiple Myeloma
- Isatuximab
- +2 more
- San Francisco, California
- +3 more
2022-01-31
Jan 31, 2022O
Not yet recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +2 more
- Portland, OregonOHSU Knight Cancer Institute
2022-03-11
Mar 11, 2022C
Completed
- Multiple Myeloma
- Carfilzomib
- +2 more
- Edmonton, Alberta, Canada
- +8 more
2022-02-01
Feb 1, 2022U
Completed
- Lymphoma, Non-Hodgkin
- Lymphoma
- Carfilzomib
- +2 more
- Davis, California
- +2 more
2021-04-21
Apr 21, 2021U
Recruiting
- Myeloma
- Multiple Myeloma
- Daratumumab
- +3 more
- Chicago, IllinoisThe University of Chicago
2021-09-15
Sep 15, 2021M
Completed
- Contiguous Stage II Adult Lymphoblastic Lymphoma
- +5 more
- carfilzomib
- +10 more
- Sacramento, CaliforniaUniversity of California Davis
2022-03-08
Mar 8, 2022B
Recruiting
- Relapsed/Refractory Multiple Myeloma
- BGB-11417
- +2 more
- Melbourne, Victoria, Australia
- +2 more
2022-03-01
Mar 1, 2022H
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
Recruiting
- Multiple Myeloma
- Carfilzomib
- +3 more
- Hackensack, New JerseyHackensack Meridian Health - John Theurer Cancer Center
2022-04-01
Apr 1, 2022U
Active, not recruiting
- Peripheral T Cell Lymphoma
- Romidepsin
- Carfilzomib
- Birmingham, United Kingdom
- +12 more
2021-10-01
Oct 1, 2021S
Completed
- Neuroendocrine Cancer
- Carfilzomib
- Denver, Colorado
- +9 more
2021-06-21
Jun 21, 2021P
Recruiting
- Relapsed Solid Tumors
- +3 more
- Carfilzomib
- +2 more
- Phoenix, Arizona
- +7 more
2021-07-06
Jul 6, 2021O
Recruiting
- Myeloma
- Carfilzomib
- +3 more
- Copenhagen, Denmark
- +3 more
2021-09-15
Sep 15, 2021T
Completed
- Myeloma Multiple
- +3 more
- Carfilzomib
- +3 more
- Afula, Israel
- +13 more
2022-01-26
Jan 26, 2022O
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +5 more
- Encinitas, California
- +6 more
2020-08-12
Aug 12, 2020M
Active, not recruiting
- MULTIPLE MYELOMA (MM)
- Carfilzomib
- +3 more
- Rionero in Vulture, ItalyIRCCS--CROB --CROB di Rionero in di Rionero in Vulture
2021-04-28
Apr 28, 2021E
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- Kiel, Germany
- +2 more
2021-01-25
Jan 25, 2021S
M
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
- Basking Ridge, New Jersey
- +5 more
2021-11-18
Nov 18, 2021M
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +5 more
- Rochester, MinnesotaMayo Clinic in Rochester
2021-11-01
Nov 1, 2021N
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +2 more
- New Haven, Connecticut
- +4 more
2022-02-01
Feb 1, 2022